NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients

INTRODUCTION: Chronic kidney disease (CKD) has a prevalence of 9.1% globally, and frequently results in elevated serum phosphate, increasing cardiovascular morbidity and mortality risk in hemodialysis (HD) patients. DS-2330b, an oral NaPi-IIb inhibitor, reduced intestinal phosphate absorption in pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Sonomi, Marbury, Thomas C., Connaire, Jeffrey, Ries, Daniel, Maxwell, William, Rambaran, Curtis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938184/
https://www.ncbi.nlm.nih.gov/pubmed/33732982
http://dx.doi.org/10.1016/j.ekir.2020.12.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938184/
https://www.ncbi.nlm.nih.gov/pubmed/33732982
http://dx.doi.org/10.1016/j.ekir.2020.12.017

Ejemplares similares